Corium Revenue and Competitors
Estimated Revenue & Valuation
- Corium's estimated annual revenue is currently $35M per year.
- Corium's estimated revenue per employee is $65,421
Employee Data
- Corium has 535 Employees.
- Corium grew their employee count by 1% last year.
What Is Corium?
Corium International, Inc. is a leader in applying advanced transdermal delivery systems and related technologies to address unmet medical needs. We have developed two highly differentiated state of the art transdermal technologies: MicroCor®, a biodegradable microstructure patch technology for active delivery of proteins, peptides and vaccines large molecules that require active transport through the skin Corplex™, a novel adhesive system and patch technology for delivery of small molecules that may otherwise be difficult to formulate and deliver With a team that includes the innovators of many of the market-leading transdermal products, Corium combines great technologies with a strong track record of successfully designing, developing and producing therapeutic products.
keywords:N/AN/A
Total Funding
535
Number of Employees
$35M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Corium News
Vaccines Delivery Devices Market Size 2022-2030| Key Players 3M, BD, Corium International, Gerresheimer ... New Jersey, USA,- The research study...
Corium's Adlarity (donepezil hydrochloride) has recently received FDA approval as a treatment for patients with mild, moderate,...
BOSTON, March 28, 2022 /PRNewswire/ -- Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization...
Featured companies: AstraZeneca, Atlantis Components, Cara Therapeutics, CardioMems, Corium International, New Ortho Polymers, Osprey Pharmaceuticals, Othera Pharmaceuticals, StrataGent Life Sciences Corium acquires Stratagent, raises $25.1M for “transdermal” drugs — Corium International, a Men ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $155.3M | 552 | 6% | $320M |
#2 | $15M | 557 | 7% | N/A |
#3 | N/A | 569 | 13% | N/A |
#4 | $15M | 582 | 15% | N/A |
#5 | $111.7M | 628 | 22% | $61.2M |